Ironwood Pharmaceuticals beats Q3 revenue estimates, raises outlook

Ironwood Pharmaceuticals

10/11/2025 12:18

Overview

Ironwood Q3 2025 revenue rises 33% yr/yr, beating analyst expectations

Adjusted EBITDA for Q3 2025 beats estimates, reflecting strong operational performance

Company raises full-year 2025 guidance for LINZESS U.S. net sales and adjusted EBITDA

Outlook

Ironwood raises 2025 LINZESS U.S. net sales guidance to $860 - $890 mln

Company increases 2025 total revenue guidance to $290 - $310 mln

Ironwood expects 2025 adjusted EBITDA to exceed $135 mln

Result Drivers

LINZESS DEMAND - Strong prescription demand growth and improved net pricing drove Q3 results, according to CEO Tom McCourt

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$122.06 mln
$74.70 mln (5 Analysts)
Q3 EPS
$0.23
Q3 Adjusted Net Income
Beat
$41.93 mln
$19.80 mln (2 Analysts)
Q3 Net Income
$40.08 mln
Q3 Adjusted EBITDA
Beat
$81.81 mln
$35.60 mln (3 Analysts)
Q3 Basic EPS
$0.25


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Ironwood Pharmaceuticals Inc is $1.00, about 92% below its November 7 closing price of $1.92

The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 5 three months ago

Press Release: ID:nBwbNBYBha

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)